BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 16525497)

  • 21. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.
    Dabaghmanesh N; Matsubara A; Miyake A; Nakano K; Ishida T; Katano H; Horie R; Umezawa K; Watanabe T
    Cancer Sci; 2009 Apr; 100(4):737-46. PubMed ID: 19469019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo.
    Yasuda A; Kondo S; Nagumo T; Tsukamoto H; Mukudai Y; Umezawa K; Shintani S
    Oral Oncol; 2011 May; 47(5):334-9. PubMed ID: 21459660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
    Horiuchi K; Morioka H; Nishimoto K; Suzuki Y; Susa M; Nakayama R; Kawai A; Sonobe H; Takaishi H; Ozaki T; Yabe H; Umezawa K; Toyama Y
    Cancer Lett; 2008 Dec; 272(2):336-44. PubMed ID: 18760530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
    Paulus A; Masood A; Miller KC; Khan AN; Akhtar D; Advani P; Foran J; Rivera C; Roy V; Colon-Otero G; Chitta K; Chanan-Khan A
    Br J Haematol; 2014 Apr; 165(1):78-88. PubMed ID: 24467634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ.
    Miyake A; Dewan MZ; Ishida T; Watanabe M; Honda M; Sata T; Yamamoto N; Umezawa K; Watanabe T; Horie R
    Microbes Infect; 2008 Jun; 10(7):748-56. PubMed ID: 18538617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
    Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
    Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
    de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
    Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells.
    Romano MF; Lamberti A; Tassone P; Alfinito F; Costantini S; Chiurazzi F; Defrance T; Bonelli P; Tuccillo F; Turco MC; Venuta S
    Blood; 1998 Aug; 92(3):990-5. PubMed ID: 9680368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines.
    Ramos PMM; Pezuk JA; Castro-Gamero AM; Oliveira HF; Scrideli CA; Umezawa K; Tone LG
    Anticancer Agents Med Chem; 2018; 18(4):541-549. PubMed ID: 29141555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
    Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P
    PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
    Hewamana S; Lin TT; Jenkins C; Burnett AK; Jordan CT; Fegan C; Brennan P; Rowntree C; Pepper C
    Clin Cancer Res; 2008 Dec; 14(24):8102-11. PubMed ID: 19088025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.
    Siegmund B; Welsch J; Loher F; Meinhardt G; Emmerich B; Endres S; Eigler A
    Leukemia; 2001 Oct; 15(10):1564-71. PubMed ID: 11587214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor.
    Matsumoto G; Muta M; Umezawa K; Suzuki T; Misumi K; Tsuruta K; Okamoto A; Toi M
    Int J Oncol; 2005 Nov; 27(5):1247-55. PubMed ID: 16211219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
    Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
    Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.
    Celegato M; Borghese C; Umezawa K; Casagrande N; Colombatti A; Carbone A; Aldinucci D
    Cancer Lett; 2014 Jul; 349(1):26-34. PubMed ID: 24704296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway.
    Escobar-Díaz E; López-Martín EM; Hernández del Cerro M; Puig-Kroger A; Soto-Cerrato V; Montaner B; Giralt E; García-Marco JA; Pérez-Tomás R; Garcia-Pardo A
    Leukemia; 2005 Apr; 19(4):572-9. PubMed ID: 15744353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.
    Lampiasi N; Azzolina A; Umezawa K; Montalto G; McCubrey JA; Cervello M
    Cancer Lett; 2012 Sep; 322(1):35-44. PubMed ID: 22343223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical assessment of curcumin as a potential therapy for B-CLL.
    Everett PC; Meyers JA; Makkinje A; Rabbi M; Lerner A
    Am J Hematol; 2007 Jan; 82(1):23-30. PubMed ID: 16947318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Shinoda K; Nakagawa K; Kosaka T; Tanaka N; Maeda T; Kono H; Mizuno R; Kikuchi E; Miyajima A; Umezawa K; Oya M
    Hum Immunol; 2010 Aug; 71(8):763-70. PubMed ID: 20573582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.